TGFB1 and colorectal carcinoma: In our previous work, we analyzed multiple patient cohorts and identified a CMS4-like subset within MSI CRC, demonstrating the TGFβ-rich TME along with a high ICI resistance signature, suggesting that strategies of TGFβ inhibition combined with ICIs may have potential therapeutic value for some MSI CRCs [15].